NASDAQ:HRTX - Heron Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.97 -1.09 (-4.18 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$24.97
Today's Range$24.87 - $26.57
52-Week Range$15.40 - $42.90
Volume645,082 shs
Average Volume819,333 shs
Market Capitalization$2.03 billion
P/E Ratio6.84
Dividend YieldN/A
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:HRTX
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio7.18
Quick Ratio6.69


Trailing P/E Ratio6.84
Forward P/E Ratio-10.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.77 million
Price / Sales63.31
Cash Flow$2.9585 per share
Price / Cash Flow8.44
Book Value$2.03 per share
Price / Book12.30


EPS (Most Recent Fiscal Year)$3.65
Net Income$-197,480,000.00
Net Margins-326.79%
Return on Equity-72.23%
Return on Assets-54.83%


Outstanding Shares78,020,000
Market Cap$2.03 billion

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.05. The biotechnology company earned $19.79 million during the quarter, compared to analysts' expectations of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The business's quarterly revenue was up 130.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.77) earnings per share. View Heron Therapeutics' Earnings History.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Heron Therapeutics.

What price target have analysts set for HRTX?

11 analysts have issued 1-year price objectives for Heron Therapeutics' stock. Their predictions range from $41.00 to $80.00. On average, they anticipate Heron Therapeutics' share price to reach $53.90 in the next twelve months. This suggests a possible upside of 115.9% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.

What is the consensus analysts' recommendation for Heron Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (11/13/2018)
  • 2. Cantor Fitzgerald analysts commented, ". Post a strong 2Q18, we are transferring coverage of HRTX and reiterating an Overweight rating and 12-month PT of $50. HRTX has successfully advanced HTX-011 towards a filing in the second half of this year, and we believe HTX-011’s uptake and peak sales potential could exceed Street estimates and our own. We expect upward earnings revisions, along with an approval of HTX-011, to drive HRTX shares higher. We expect upside to come from Cinvanti and HTX-011. Additionally, we believe that HRTX’s decision to retain global rights to HTX-011 could make HRTX an attractive addition to a larger company’s portfolio, or provide further upside to HRTX revenue estimates." (8/8/2018)
  • 3. Mizuho analysts commented, "We expect HTX-011 to receive broad label and we see potential for a quicker review process by the FDA for a mid-2019 approval. We reiterate our Buy rating and raise our PT to $41." (6/22/2018)
  • 4. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)

Has Heron Therapeutics been receiving favorable news coverage?

News articles about HRTX stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Heron Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days.

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:
  • Dr. Barry D. Quart, CEO & Director (Age 61)
  • Mr. Robert H. Rosen, Pres & Director (Age 62)
  • Mr. Robert E. Hoffman CPA, CFO & Sr. VP of Fin. (Age 52)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 58)
  • Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 44)

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (12.34%), Vanguard Group Inc. (7.94%), Vanguard Group Inc (7.94%), Tang Capital Management LLC (7.63%), Franklin Resources Inc. (7.51%) and Janus Henderson Group PLC (6.98%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Which institutional investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, FMR LLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Morgan Stanley, Federated Investors Inc. PA, Castleark Management LLC and Franklin Resources Inc.. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Insider Buying and Selling for Heron Therapeutics.

Which institutional investors are buying Heron Therapeutics stock?

HRTX stock was bought by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Vanguard Group Inc, Vanguard Group Inc., Rubric Capital Management LP, Stelliam Investment Management LP, Candriam Luxembourg S.C.A., Kavi Asset Management LP and BlackRock Inc.. View Insider Buying and Selling for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $24.97.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $2.03 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  498 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  762
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel